Teva pharmaceutical sees revenue grow in first quarter

Thursday 01 May 2014 16.16
Teva produces a range of products, including cancer therapies, oral contraceptives and pain medicines
Teva produces a range of products, including cancer therapies, oral contraceptives and pain medicines

Pharmaceutical group Teva has reported revenues of $5bn for the first three months of 2014; up 2% on the same period of last year.

The company, which employs 467 at facilities in Dundalk and Waterford, also said it was now the largest supplier of prescription medicines in Ireland; distributing 11,000 packs of medicine per day.

Teva, which produces a range of products including cancer therapies and oral contraceptives, recorded an income of $744m during the quarter when using generally accepted accountancy principles.

This was an increase of 18% on the income it generated in the first three months of 2013.

Based on this the company has reaffirmed its full year and earnings-per-share guidance for 2014.